Tag: ISIS

Isis Update (9-23-13)

ISIS Presents More Impressive Phase II Data for APOCIII-Rx at NLA – Over the weekend, ISIS presented data on APOCIII-Rx in patients with familial chylomicronemia syndrome (FCS) at the National Lipid Association (NLA) meeting. FCS is a rare disease that only affects 3,000-5,000 patients globally and is characterized by severely high triglyceride (TG) levels. The[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (9-3-13)

ISIS Delivers Powerful Phase II Data for APOCIII-Rx – Raising BUY LIMIT and PRICE TARGET – Isis has presented rather positive Phase II data for APOCIIIRx in patients with high triglycerides and Type 2 diabetes at the American Diabetes Association (ADA) meeting.  In our view, this is a major unexpected surprise in the ISIS story[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (2-19-13)

GSK Begins Pivotal Trial For ISIS-TTR.  The company earned a $7.5 million milestone payment from their partner, GlaxoSmithKline (GSK), on the initiation of a Phase II/III trial for ISIS-TTR.  ISIS-TTR is an antisense drug development candidate for the treatment of transthyretin (TTR) amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (12-14-12)

Isis had bad news this morning and the stock is actually up. The company and its partner Genzyme announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for its marketing authorization application (MAA) for Kynamro for the treatment of patients with Homozygous[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (9-19-13)

ISIS – Sustainable Responses Reported in Updated Phase I Data for SMN-Rx in Children with SMA:  Isis announced this morning follow-up preliminary data from a single dose, open-label Phase I study of SMN-Rx in children with spinal muscular atrophy (SMA), show that most SMA children receiving the two highest doses of the drug (6 mg[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (6-24-13)

ISIS Delivers Powerful Phase II Data for APOCIII-Rx – Raising BUY LIMIT and PRICE TARGET – Isis has presented rather positive Phase II data for APOCIIIRx in patients with high triglycerides and Type 2 diabetes at the American Diabetes Association (ADA) meeting.  In our view, this is a major unexpected surprise in the ISIS story[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

[*Breaking News*] Isis Update (1-31-13)

Isis’ Kynamro was approved by the FDA for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The approval is the first for a systemic antisense drug (Vitravene for CMV of the eye was approved in 1998), and represents a major milestone for the Company’s antisense technology. The FDA approval triggers a $25 million milestone payment[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (9-9-13)

ISIS And BIIB Ink Another Big Deal For Neuro:  Isis and Biogen Idec have entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. The agreement combines BIIB’s expertise in neurology with ISIS’ leadership in antisense technology to develop novel therapies to treat neurological disorders. This is the[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (2-26-13)

ISIS Starts Phase II Study for ISIS-CRP. ISIS also initiated Phase II trials with ISIS-CRP, which targets C-reactive protein (CRP), which is elevated in many inflammatory diseases, in patients with atrial fibrillation (AF). The goal is to reduce the frequency of AF episodes and provide proof-of-principle for CRP as a drug development target.  In addition, ISIS[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Isis Update (1-18-13)

Isis’ stock has been strong, pre- and post-JP Morgan. Wall Street is beginning to warm up to the story, as we believe; the deep pipeline from late-stage to early-stage compounds is attracting more investors.  The recent partnerships with Biogen and AstraZeneca for certain early-stage drug development candidates have convinced some that antisense has real potential. The[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by